Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,099
  • Shares Outstanding, K 8,178
  • Annual Sales, $ 120,770 K
  • Annual Income, $ 32,690 K
  • EBIT $ 36 M
  • EBITDA $ 38 M
  • 60-Month Beta -0.34
  • Price/Sales 0.35
  • Price/Cash Flow 1.08
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $3.50
  • Growth Rate Est. (year over year) +28,442.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +22.56%
on 03/30/26
5.55 -5.00%
on 04/17/26
+0.04 (+0.76%)
since 03/17/26
3-Month
3.92 +34.44%
on 02/23/26
7.30 -27.81%
on 03/09/26
+0.73 (+16.08%)
since 01/16/26
52-Week
3.92 +34.44%
on 02/23/26
19.15 -72.47%
on 01/05/26
-0.90 (-14.59%)
since 04/17/25

Most Recent Stories

More News
REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 – Contact Kirby McInerney LLP

Kirby McInerney LLP reminds Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a pending federal...

ATRA : 5.27 (+0.57%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , April 17, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

ATRA : 5.27 (+0.57%)
ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO , April 16, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics,...

ATRA : 5.27 (+0.57%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain...

ATRA : 5.27 (+0.57%)
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , April 14, 2026 /PRNewswire/ --

ATRA : 5.27 (+0.57%)
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA).

ATRA : 5.27 (+0.57%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

ATRA : 5.27 (+0.57%)
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options

ATRA : 5.27 (+0.57%)
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 7, 2026 /PRNewswire/ --  The Law Offices of Frank R. Cruz announces that investors with losses related to Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:...

ATRA : 5.27 (+0.57%)
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) .

ATRA : 5.27 (+0.57%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 5.75
2nd Resistance Point 5.65
1st Resistance Point 5.46
Last Price 5.27
1st Support Level 5.17
2nd Support Level 5.07
3rd Support Level 4.88

See More

52-Week High 19.15
Fibonacci 61.8% 13.33
Fibonacci 50% 11.53
Fibonacci 38.2% 9.74
Last Price 5.27
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.